ANALYSIS: Hanmi Deal Strengthens BI’s Hand But Competitors Ahead

Hanmi’s third-generation EGFR inhibitor HM61713, acquired for $50 million up front, strongly complements Boehringer Ingelheim’s existing oncology drug Gilotrif/Giotrif, but the new asset is facing competitors from AstraZeneca and Clovis that are more advanced in development.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia